Overview

Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of rizatriptan, alone or combined with caffeine for treating acute attacks of migraine. Each subject will have 3 months to treat 3 acute migraine headache attacks. Each subject will be dispensed one box containing 3 packets of study medication labeled for Headache #1, Headache #2, or Headache #3. Each packet wil contain either Maxalt 10mg MLT or a Maxalt placebo (sugar pill), and a capsule containing either caffeine 75mg or a capsule containing placebo (sugar). One headache will be treated with a combination of Maxalt 10mg MLT and caffeine. Another headache will be treated with a combination of Maxalt 10mg MLT and a capsule containing placebo. A third headache will be treated with just placebo. Neither the subject, the study coordinator, or your study doctor will know in which order you will receive the three different treatments. This information is available in case of emergency.
Phase:
Phase 3
Details
Lead Sponsor:
Diamond Headache Clinic
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Caffeine
Rizatriptan